http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4014260-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0efa077d881a96aeb1e29b21ef1bbb58 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-815 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-815 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate | 1990-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1b09b1fb1e38e76c66339e88af65da9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faf6668db64b40c2ff2ca68500dfaa00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd58d390727984cabc841c0e8993ba66 |
| publicationDate | 1991-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-4014260-A1 |
| titleOfInvention | HIRUDINPOLYALKYLENE GLYCOL CONJUGATES |
| abstract | Hirudin-polyalkylene glycol conjugates (I) (A-(CH2)n-(O-(CH2)n)m-B-)pHir are new. In (I): A=OH, NH2, CH3CONH, COOH, COOR or OR; R = 1-4C alkyl; B = direct bond or a linker; Hir = hirudin, desulphatohirudin or hirudin mutein gp. linked via serine, threonine or lysine chain(s); m = 100-1000; n = 2-5; p = 1-4. Pref. the linker is (a) -O-(CH2)n-1-CH= or -O-(CH2)n-1-CO-; or (b) -X-CO-, -X-CO-NH-Z-NH-CO-, -X-CH2-p-Ph-N2-, -X-CH2-CH(OH)-CH2-p-Ph-N2-, -X-CO-CH2-CH2-CO-, -X-CH2-CO- or gp. of formula (i); R1 = H, Cl or OH; X = -S-, -O-, -N(H, CH3 or C2H5)-; and Z = 2-6C alkylene or p-phenylene. USE/ADVANTAGE - (I) are anticoagulants in human and veterinary medicine to treat and prevent e.g. myocardial infarct, peripheral arterial occlusions, deep vein thrombosis and pulmonary embolism. They are administered i.v. or i.m. (I) have a half-life of 1-100 hours, compared with 50 mins. for hirudin itself and 7 hours for hirudin-dextran. Further, (I) have high activity with only very slight antigenicity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5919762-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9515183-A1 |
| priorityDate | 1989-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.